文献速递浆细胞疾病

适合移植的新诊断多发性骨髓瘤患者接受达雷妥尤单抗、来那度胺、硼替佐米和地塞米松治疗的健康相关生活质量:GRIFFIN研究患者报告结局

Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
PubMed 文献 · Am J Hematol · 2024-04-15

GRIFFIN是一项2期试验,在适合移植的新诊断多发性骨髓瘤患者中,D-RVd较RVd改善缓解深度和无进展生存期。本文报告患者报告结局,多数量表在巩固治疗后出现有意义的改善并持续至少2年维持治疗,疼痛症状大幅减轻(约20分),D-RVd组多数时间点数值更高。

要点

  • D-RVd与RVd两方案在巩固治疗后多数患者报告结局量表较基线有临床意义改善,并持续至少2年维持治疗。
  • 两治疗组疼痛症状均较基线大幅降低(约20分),D-RVd组多数时间点数值更高。
  • 整体健康状况、疲劳症状和躯体功能等关键量表在两方案中均见改善。

核心结论

  • D-RVd与RVd均使适合移植的新诊断多发性骨髓瘤患者多数患者报告结局量表较基线有临床意义改善,并持续至少2年维持治疗,这些生活质量改善支持D-RVd在诱导、巩固和维持治疗中临床结局(如缓解率和PFS)的改善。

研究设计与样本

  • 2期GRIFFIN试验(ClinicalTrials.gov标识符NCT02874742),在适合移植的新诊断多发性骨髓瘤患者中比较D-RVd与RVd,本文报告采用EORTC QLQ-C30、QLQ-MY20和EQ-5D-5L工具收集的患者报告结局。

主要发现

  • 两治疗组在巩固治疗后多数患者报告结局量表较基线有临床意义改善,并持续至少2年维持治疗。
  • 两治疗组疼痛症状均较基线大幅降低(约20分),D-RVd组在多数时间点数值更高。
  • D-RVd与RVd两方案均见整体健康状况、疲劳症状和躯体功能等关键量表改善。

关键数值与推荐

  • 患者报告结局评估时间点为第1、2、3周期第1天,第4周期第21天(诱导治疗结束),第5周期第1天,第6周期第21天(移植后巩固治疗结束),以及维持治疗第6、12、18和24个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 2 GRIFFIN trial (ClinicalTrials.gov identifier: NCT02874742), daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd) improved depth of response and progression-free survival (PFS) versus lenalidomide, bortezomib, and dexamethasone (RVd) alone in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes (PROs) collected using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30-item (QLQ-C30), EORTC Quality of Life Questionnaire Multiple Myeloma Module 20-item (QLQ-MY20), and EuroQol 5-Dimension 5-Level (EQ-5D-5L) tools on day 1 of cycles 1, 2, and 3; on day 21 of cycle 4 (end of induction therapy); on day 1 of cycle 5; on day 21 of cycle 6 (end of posttransplant consolidation therapy); and at months 6, 12, 18, and 24 of maintenance therapy. Meaningful improvements from baseline were seen in most of the PRO scales with both treatments after consolidation and were sustained for at least 2 years of maintenance treatment. Large reductions from baseline (~20 points) were especially observed in pain symptoms for both treatment groups, although these were numerically higher for patients receiving D-RVd during the majority of the time points. In addition, improvements in key scales, such as global health status, fatigue symptoms, and physical functioning, were also seen with both D-RVd and RVd. These improvements in health-related quality of life contribute to the totality of evidence supporting the improvement in clinical outcomes such as response rates and PFS with D-RVd in induction, consolidation, and maintenance therapy in TE patients with NDMM.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Silbermann R, Laubach J, Kaufman JL, et al. Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024. PMID: 38622840. doi:10.1002/ajh.27326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。